Inventor · disambiguated record
Lori Friedman
Also filed as: FRIEDMAN LORI · FRIEDMAN LORI S · FRIEDMAN LORI SICKELS
25 granted patents·48 pending applications·207 citations·filing 1995–2022
95Inventor score
Top patents by PatentIndex Score
73 records- 0196US9107926B2Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancerGENENTECH INC·Filed 2013·Granted Aug 18, 2015·28 cites·11 claims
- 0292US8247397B2Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of useBELVIN MARCIA·Filed 2008·Granted Aug 21, 2012·40 cites·34 claims
- 0391US8604014B2Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of useBELVIN MARCIA·Filed 2011·Granted Dec 10, 2013·26 cites·15 claims
- 0487US9855270B2Methods and compositions for modulating estrogen receptor mutantsGENENTECH INC·Filed 2015·Granted Jan 2, 2018·4 cites·35 claims
- 0583US8536161B2Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignanciesEBENS JR ALLEN J·Filed 2010·Granted Sep 17, 2013·6 cites·19 claims
- 0680US5622829AGenetic markers for breast, ovarian, and prostatic cancerUNIV CALIFORNIA·Filed 1995·Granted Apr 22, 1997·66 cites·26 claims
- 0779US7993829B2HPRP4s modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2007·Granted Aug 9, 2011·2 cites·10 claims
- 0871US9335320B2Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignanciesGENENTECH INC·Filed 2013·Granted May 10, 2016·1 cites·4 claims
- 0971US7785805B2MAN2As as modifiers of the IGFR pathway and methods of useEXELIXIS INC·Filed 2005·Granted Aug 31, 2010·4 cites·16 claims
- 1071US5821328AGenetic markers for breast, ovarian, and prostatic cancerUNIV CALIFORNIA·Filed 1997·Granted Oct 13, 1998·18 cites·13 claims
- 1169US8426147B2RORS as modifiers of the p21 pathway and methods of useFRANCIS-LANG HELEN·Filed 2008·Granted Apr 23, 2013·2 cites·15 claims
- 1269US7888047B2PDEs as modifiers of the IGFR pathways and methods of useEXELIXIS INC·Filed 2005·Granted Feb 15, 2011·1 cites·22 claims
- 1369US2008102070A1SCDs As Modifiers of the p53 Pathway and Methods of UseEXELIXIS INC·Filed 2007·Application pending·0 cites
- 1468US2008166709A1MARKs as Modifiers of the p53 Pathway and Methods of UseEXELIXIS INC·Filed 2007·Application pending·0 cites
- 1567US6762291B1Insect p53 tumor suppressor genes and proteinsEXELIXIS INC·Filed 2000·Granted Jul 13, 2004·2 cites·2 claims
- 1666US2008241131A1SPHKS as modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2008·Application pending·0 cites
- 1764US6924117B2Human RRP sequences and methods of useEXELIXIS INC·Filed 2001·Granted Aug 2, 2005·2 cites·5 claims
- 1863US2018280408A1Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancerGENENTECH INC·Filed 2018·Application pending·0 cites
- 1962US2003165966A1MSRAs as modifiers of the p53 pathway and methods of useFiled 2003·Application pending·0 cites
- 2060US2023088701A1Combination therapies for treatment of breast cancerGENENTECH INC·Filed 2022·Application pending·0 cites
- 2159US2010275275A1HADHs as Modifiers of the p21 Pathway and Methods of UseEXELIXIS INC·Filed 2009·Application pending·0 cites
- 2256US2016045515A1Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancerGENENTECH INC·Filed 2015·Application pending·0 cites
- 2354US6972179B2RRP sequences and knockout mice and uses thereofEXELIXIS INC·Filed 2002·Granted Dec 6, 2005·0 cites·5 claims
- 2454US2024398811A1Prc2 inhibitors for use in treating blood disordersORIC PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2554US2013345217A1Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of useGENENTECH INC·Filed 2013·Application pending·0 cites
- 2654US2006160764A1LIMKs as modifiers of p53 pathway and methods of useEXELIXIS INC·Filed 2006·Application pending·0 cites
- 2753US8771942B2SCDs as modifiers of the p53 pathway and methods of useBELVIN MARCIA·Filed 2010·Granted Jul 8, 2014·0 cites·6 claims
- 2853US7049088B2PRMTs as modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2002·Granted May 23, 2006·1 cites·2 claims
- 2952US8153384B2Marks as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2010·Granted Apr 10, 2012·0 cites·15 claims
- 3052US2006101530A1Rors as modifiers of the p21 pathway and methods of useFRANCIS-LANG HELEN·Filed 2003·Application pending·0 cites
- 3152US2023302014A1Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinationsORIC PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3251US8268548B2MAP3Ks as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2007·Granted Sep 18, 2012·0 cites·12 claims
- 3351US2005181481A1HADHs as modifiers of the p21 pathway and methods of useEXELIXIS INC·Filed 2005·Application pending·0 cites
- 3451US2004161827A1Insect p53 tumor suppressor genes and proteinsFiled 2004·Application pending·0 cites
- 3551US2005227228A1Map3ks as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2002·Application pending·0 cites
- 3651US2005186200A1HADHs as modifiers of the p21 pathway and methods of useEXELIXIS INC·Filed 2005·Application pending·0 cites
- 3750US2003215849A1PDPK1s as modifiers of the p53 pathway and methods of useFiled 2003·Application pending·0 cites
- 3850US2003087266A1IGs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 3950US2003219795A1SCDs as modifiers of the p53 pathway and methods of useFiled 2003·Application pending·0 cites
- 4050US2011159508A1GFATS as Modifiers of the P53 Pathway and Methods of UseEXELIXIS INC·Filed 2010·Application pending·0 cites
- 4148US7943302B2C20ORF23 as modifier of the IGFR pathway and methods of useEXELIXIS INC·Filed 2005·Granted May 17, 2011·0 cites·7 claims
- 4248US2003027230A1HPRP4s as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 4347US6927022B2HADHs as modifiers of the p21 pathway and methods of useEXELIXIS INC·Filed 2002·Granted Aug 9, 2005·0 cites·21 claims
- 4447US2010183583A1Galk1s as modifiers of the pten/akt pathway and methods of useEXELIXIS INC·Filed 2006·Application pending·0 cites
- 4547US2011135629A1EYA2S As Modifiers of the PTEN/AKT Pathway and Methods of UseEXELIXIS INC·Filed 2006·Application pending·0 cites
- 4647US2005112568A1Dgks as modifiers of the p53 pathwha and methods of useFiled 2002·Application pending·0 cites
- 4747US2003013144A1HS2STs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 4847US2005170344A1Chds as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 4947US2003165809A1MARKs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 5047US2002192695A1PIBs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
Showing the top 50 of 73 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →